BioPortfolio News: Takeda Pharmaceutical Company Limited - Takeda Receives New Information on...

Friday 6th of March 2009 2:54

SYR-322 New Drug Application Takeda Receives New Information on Alogliptin (SYR-322) NDA. Takeda Receives New Information on Alogliptin (SYR-322) NDA ...
http://www.drugs.com/nda/syr_322_090306.html...

Takeda Receives New Information on Alogliptin (SYR-322) NDA Takeda Receives New Information on Alogliptin (SYR-322) NDA. OSAKA, Japan , March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=ind_focus....

SYR-322 New Drug Application 27 Jun 2009 ... Takeda Receives New Information on Alogliptin (SYR-322) NDA - March 6, 2009. Takeda Receives New Action Date for Alogliptin (SYR-322) NDA ...
http://www.drugs.com/nda/syr_322_090628.html...

Archive News & Video for Friday, 06 Mar, 2009 | Reuters.com 6 Mar 2009 ... Takeda Receives New Information on Alogliptin (SYR-322) NDA 02:54 AM EST. Pakistani police say making progress on attackers 02:53 AM EST ...
http://www.reuters.com/resources/archive/us/20090306.html...

Drugs.com - New Drug Applications Archive March 2009 March 6, Takeda Receives New Information on Alogliptin (SYR-322) NDA. March 9, FDA Appeal Decision Indicates that Genasense Approval in Chronic Lymphocytic ...
http://www.drugs.com/new-drug-applications-archive/March-200...

Takeda Pharmaceutical Company Limited

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

Takeda Receives New Information on Alogliptin (SYR-322) NDA